$BIOC News

Last published 3y ago

3y agoBIOCEnrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept's CNSide™ Assay to Evaluate Patients with Leptomeningeal MetastasesBusiness WireBiocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious
3y agoBIOC PSTVBiocept Signs CNSide™ Licensing Agreement with Plus TherapeuticsBusiness WireBiocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc.
3y agoBIOCBiocept to Participate in the H.C. Wainwright Global Investment ConferenceBusiness WireBiocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and services, announces that management will participate in the H.C. Wainwright 25th Annual Global
3y agoBIOCBiocept, Inc. (BIOC) Business Update Conference Call (Transcript)Earnings Call Transcripts
3y agoBIOCBiocept to Hold Business Update Conference Call on August 30, 2023Business WireBiocept, Inc. (NASDAQ:BIOC) management will hold a conference call on August 30, 2023, beginning at 4:00 p.m. Eastern time (1:00 p.m. Pacific time) to provide a business update and to answer questions. Participants
3y agoBIOCBiocept Reports Second Quarter 2023 Financial ResultsBusiness WireBiocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2023 and provides a business
3y agoBIOCBiocept's CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer ConferenceBusiness WireBiocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and services, announces that its CNSide cerebrospinal fluid assay was featured in two oral
3y agoBIOCBiocept Announces the Passing of Board Chair M. Faye WilsonBusiness WireBiocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company") announces that M. Faye Wilson, Board Chair, passed away unexpectedly on Monday, July 10. The Board of Directors and staff of Biocept extend their deepest
3y agoBIOCBiocept Names Antonino Morales as President and Chief Executive OfficerBusiness WireSamuel D. Riccitelli resigns as interim President and CEO, and Director Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and services, has named
3y agoBIOCBiocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023Business WireBiocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and service, announces that management will present at the Maxim Group Virtual Healthcare Conference
3y agoBIOCScientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept's CNSide™ Versus CytologyBusiness WireReal-world retrospective study showed increased sensitivity for CNSide relative to standard cerebral spinal fluid (CSF) cytology in detecting leptomeningeal metastases Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the
3y agoBIOCBiocept Announces Pricing of $5.0 Million Underwritten Public OfferingBusiness WireBiocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and service, announces the pricing of an underwritten public offering of 1,176,470 shares of its
3y agoBIOCBiocept Announces One-for-Thirty Reverse Stock SplitBusiness WireBiocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces that as a result of its 1-for-30 reverse stock split that became effective at 4:05 p.m. Eastern Time on
3y agoBIOCBiocept Reports First Quarter 2023 Financial ResultsBusiness WireBiocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2023 and provides a business update. "I'm
3y agoBIOCBiocept Reports 2022 Financial ResultsBusiness WireBiocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the 12 months ended December 31, 2022 and provides a business update. "I could not
3y agoBIOCEnrollment Begins in FORESEE Clinical Trial Using Biocept's CNSide™ to Evaluate Patients with Leptomeningeal MetastasesBusiness WireBiocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces enrollment of the first patient in the FORESEE clinical trial with the Company's proprietary cerebrospinal
3y agoBIOCBiocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireBiocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 7,360 shares of its common
3y agoBIOCBiocept to Explore Strategic Alternatives and Implement Restructuring PlanBusiness WireBiocept, Inc. (NasdaqCM: BIOC) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Biocept has engaged EF Hutton, division of Benchmark
3y agoBIOCBiocept Reports Third Quarter 2022 Financial ResultsBusiness WireCNSide™ study data featured in three poster presentations at leading neuro-oncology annual meeting Participates in UCSF investigator-initiated study to better understand the development and progression of
3y agoBIOCBiocept Appoints Financial Executive Quyen Dao-Haddock to its Board of DirectorsBusiness WireBiocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately, increasing Board
3y agoBIOCBiocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous SystemBusiness WireConducted by leading breast oncologists from UCSF under a grant from the California Breast Cancer Research Program and the University of California, San Francisco Brain Spore, the study will analyze results from
4y agoBIOCBiocept to Present at the LD Micro Main Event XVBusiness WireBiocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces that management will present at the LD Micro Main Event XV on Wednesday, October 26 at 2:30 p.m. Pacific
4y agoBIOCBiocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous SystemBusiness WireThe cerebrospinal fluid (CSF) assay is now validated for melanomas and carcinomas, providing information to help physicians improve treatment decisions for more patients with advanced cancers Biocept, Inc.
4y agoBIOCBiocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous SystemBusiness WireReal-world case studies to be presented by leading neuro-oncologists Dr. Priya U. Kumthekar of Northwestern University and Dr. Seema A. Nagpal of Stanford University Biocept, Inc. (NASDAQ:BIOC), a leading provider of
4y agoBIOCBiocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireBiocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 89,550 shares of its common stock to 12 new employees. The in
4y agoBIOCBiocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-QBusiness WireBiocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it received a notice (the "Notice") on August 17, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasd
4y agoBIOCBiocept Announces a Delay in the Filing of its Quarterly Report on Form 10-QBusiness WireBiocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products, and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. The delay is related to the ongoing account
4y agoBIOCBiocept Appoints RSM as Independent AuditorBusiness WireBiocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of RSM US LLP ("RSM") as its independent registered public accounting firm effective June 24, 2022. RSM was recently ranked
4y agoBIOC PSTVPlus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM TrialGlobeNewswireBiocept's CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden in leptomeningeal metastasis (LM) of the central nervous system Assay results will be used to evaluate response to treatment and treatment efficacy f
4y agoBIOC ICLRA Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide - NCT05414123ClinicalTrials.govAssess the impact of CNSide on treatment decisions, Evaluate CNSide as a treatment response monitoring device for LM tumors, The performance of CNSide of tumor cell detection in the CSF compared to cytology
4y agoBIOCBiocept to Hold Business Strategy Conference Call TodayBusiness WireBiocept, Inc. (NASDAQ:BIOC) management will hold a conference call today, June 7, 2022, beginning at 4:00 p.m. Eastern time to discuss its re-focused and rationalized business strategy and to answer questions. Participants can pre-register for the co
4y agoBIOCBiocept Reports First Quarter 2022 Financial ResultsBusiness WireNet revenues of $19.9 million up 12% over Q1 2021 CNSide™ assay volume up 219% over Q1 2021 and up 70% over Q4 2021 Expanded CNSide customer base with additional oncologists from six leading cancer centers Previews re-focused and rationa
4y agoBIOCBiocept Announces a Delay in the Filing of its Quarterly Report on Form 10-QBusiness WireBiocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2022. The delay is related to the ongoing ac
4y agoBIOCBiocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireBiocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 519,140 shares of its common stock to 44 new employees, inclu
4y agoBIOCBiocept Reports 2021 Fourth Quarter and Full Year Financial ResultsBusiness WireFourth quarter net revenues of $14.0 million driven by RT-PCR COVID-19 testing volume Full year net revenues of $61.2 million increased 123% over the prior year Positive operating cash flow for 2021 of $3.7 million Cash and cash equivalent
4y agoBIOCBiocept Reports Unaudited 2021 Revenue and Year-End Cash BalanceBusiness WireBiocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports unaudited net revenue for 2021 of $61.2 million and cash and cash equivalents as of December 31, 2021 of approximately $28 million. "Revenu
4y agoBIOCBiocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022Business WireBiocept, Inc. (NASDAQ:BIOC) announces that it will release financial results for the three and 12 months ended December 31, 2021 and will file its Annual Report on Form 10-K with the Securities and Exchange Commission (SEC) on Thursday, March 31, 2022.
4y agoBIOCBiocept Appoints Philippe Marchand as Chief Operating OfficerBusiness WireIndustry veteran to oversee operations for the company and its CNSide™ cerebrospinal fluid assay to aid in the management of patients with metastatic brain cancers Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, prod
4y agoBIOCBiocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireBiocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted an inducement stock option to purchase 134,550 shares of its common stock to Darrell Taylor, its new Senior Vice P
4y agoBIOCBiocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Development of Targeted Therapies for Metastatic Brain CancerBusiness WireAbility to serially monitor treatment response, identify key biomarkers and customize assay aids clinical research efforts to improve treatment for metastatic cancers involving brain and spinal cord Biocept, Inc. (NASDAQ:BIOC), a leading provider of
4y agoBIOC CSTL DOCRF SRNEIntroduction of Innovative PCR-Based Detection Methods Surges Fueled by Pandemic and Other DiseasesPR NewswirePALM BEACH, FL, Feb. 18, 2022 /PRNewswire/ -- PCR testing and the COVID-19 diagnostic testing market has, unexpectantly, been growing at a substantial rate the past few years. Countries are racing to slow down the spread of the disease by implementing ne
4y agoBIOCBiocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interim Chief Financial OfficerBusiness WireBiocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointments of Samuel D. Riccitelli as Interim President and Chief Executive Officer, succeeding Michael W. Nall, and Antonino Morales
4y agoBIOCBiocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance OfficerBusiness WireBiocept (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products, and services, has appointed Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer. With more than 30 years of healthcare experience, Tayl
4y agoBIOCBiocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron VariantBusiness WireBiocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces that COVID-19 RT-PCR testing volume has increased in 2022 with the emergence of the Omicron variant. Biocept continues to serve the communit
4y agoBIOCBiocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10Business WireBiocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held Januar
4y agoBIOCBiocept's CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the BrainBusiness WireSpotlight Presentation at SABCS showed that in 38% of patients the HER2 status of the metastatic cancer differed from the primary tumor, offering new information to aid treatment decisions Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular
4y agoBIOC DGXQuest Diagnostics Now Offers Biocept's Liquid Biopsy Test for Lung Cancer, Expanding its Menu of Advanced Cancer DiagnosticsPR NewswireSECAUCUS, N.J. and SAN DIEGO, Dec. 1, 2021 /PRNewswire/ -- Physicians in the United States can now order the liquid biopsy-based Target Selector™ NGS Lung Panel test directly from Quest Diagnostics (NYSE:DGX), the nation's leading provider of diagnost
4y agoBIOC TAUGClinical Validation is Completed for New COVID-19 Assay Designed by AEGEA Biotechnologies; Test Quantifies Viral Load to Determine Infection Level and Disease ProgressionPR NewswireSAN DIEGO, Nov. 22, 2021 /PRNewswire/ -- AEGEA Biotechnologies, Inc., an innovative life science company with an extensive portfolio of next-generation nucleic acid technologies, announces that the new PCR-based COVID-19 assay it designed has been valid
4y agoBIOCBiocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu SeasonBusiness WireBiocept continues to expand and perform COVID-19 testing services using Thermo Fisher Scientific platform Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products, and services, now offers a single test that can detect
4y agoBIOCBiocept's CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast CancerBusiness WireCase series poster to be presented at the Society for Neuro-Oncology Annual Meeting Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, today announced the presentation of a multi-institutional case